PATENT CLAIM ANALYSIS

Application Number: 16104045
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2019-02
Patent Classification: ["514", "020900"]

Abstract:
The invention features compounds of formula I or II: In one embodiment, the invention relates compounds and processes for conjugating ligand to oligonucleotide. The invention further relates to methods for treating various disorders and diseases such as viral infections, bacterial infections, parasitic infections, cancers, allergies, autoimmune diseases, immunodeficiencies and immunosuppression.

Claim (Index 1):
An oligonucleotide comprising two or more subunits of formula (I) at two or more positions that occur at 1-6 nucleotides from either end of the oligonucleotide: wherein:\n X is O, S, NR N  or CR P 2 ; \n B is hydrogen, optionally substituted natural or non-natural nucleobase, optionally substituted triazole, or optionally substituted tetrazole, NH\u2014C(O)\u2014O\u2014C(CH 2 B 1 ) 3 , NH\u2014C(O)\u2014NH\u2014C(CH 2 B 1 ) 3 ; where B 1  is independently halogen, mesylate, N 3 , CN, optionally substituted triazole or optionally substituted tetrazole, and where the nucleobase may further be substituted by -J-linker-N 3 , -J-linker-CN, -J-linker-C\u2261R 8 , -J-linker-cycloalkyne, -J-linker-R L , -Linker-Q-R L , or -J-linker-Q-linker-R L ; \n R 1 , R 2 , R 3 , R 4  and R 5  are each independently H, OR 6 , F, N(R N ) 2 , N 3 , CN, -J-linker-N 3 , -J-linker-CN, -J-linker-cycloalkyne, -J-linker-R L , -Linker-Q-R L , or -J-linker-Q-linker-R L ; \n J is absent, O, S, NR N , OC(O)NH, NHC(O)O, C(O)NH, NHC(O), NHSO, NHSO 2 , NHSO 2 NH, OC(O), C(O)O, OC(O)O, NHC(O)NH, NHC(S)NH, OC(S)NH, OP(N(R P ) 2 )O, or OP(N(R P ) 2 ); \n R 6  is hydrogen, hydroxyl protecting group, optionally substituted alkyl, optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted aralkyl, optionally substituted alkenyl, optionally substituted heteroaryl, polyethyleneglycol (PEG), a phosphate, a diphosphate, a triphosphate, a phosphonate, a phosphonothioate, a phosphonodithioate, a phosphorothioate, a phosphorothiolate, a phosphorodithioate, a phosphorothiolothionate, a phosphodiester, a phosphotriester, an activated phosphate group, an activated phosphite group, a phosphoramidite, a solid support, \u2014P(Z 1 )(Z 2 )\u2014O-nucleoside, \u2014P(Z 1 )(Z 2 )\u2014O-oligonucleotide, \u2014P(Z 1 )(Z 2 )\u2014 formula (I), \u2014P(Z 1 )(O-linker-Q-linker-R L )\u2014O-nucleoside, P(Z 1 )(O-linker-R L )\u2014O-nucleoside, \u2014P(Z 1 )(O-linker-N 3 )\u2014O-nucleoside, P(Z 1 )(O-linker-CN)\u2014O-nucleoside, P(Z 1 )(O-linker-C\u2261R 8 )\u2014O-nucleoside, P(Z 1 )(O-linker-cycloalkyne)-O-nucleoside, \u2014P(Z 1 )(O-linker-Q-linker-R L )\u2014O-oligonucleotide, P(Z 1 )(O-linker-R L )\u2014O-oligonucleotide, P(Z 1 )(O-linker-N 3 )\u2014O-oligonucleotide, \u2014P(Z 1 )(O-linker-CN)\u2014O-oligonucleotide, P(Z 1 )(O-linker-C\u2261R 8 )\u2014O-oligonucleotide, P(Z 1 )(O-linker-cycloalkyne)-O-oligonucleotide, \u2014P(Z 1 )(-linker-Q-linker-R L )\u2014O-nucleoside, \u2014P(Z 1 )(-linker-Q-R L )\u2014O-nucleoside, \u2014P(Z 1 )(-linker-N 3 )\u2014O-nucleoside, P(Z 1 )(-linker-CN)\u2014O-nucleoside, P(Z 1 )(-linker-C\u2261R 8 )\u2014O-nucleoside, P(Z 1 )(-linker-cycloalkyne)-O-nucleoside, \u2014P(Z 1 )(-linker-Q-linker-R L )\u2014O-oligonucleotide, \u2014P(Z 1 )(-linker-R L )\u2014O-oligonucleotide, P(Z 1 )(-linker-N 3 )\u2014O-oligonucleotide, \u2014P(Z 1 )(-linker-CN)\u2014O-oligonucleotide, P(Z 1 )(-linker-C\u2261R 8 )\u2014O-oligonucleotide or P(Z 1 )(-linker-cycloalkyne)-O-oligonucleotide; \n R N  is H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted aralkyl, optionally substituted heteroaryl, or an amino protecting group; \n R P  is independently H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted cycloalkyl, or optionally substituted heteroaryl; \n Q is \n R L  is a ligand; R 8  is N or CR 9 ; R 9  is H, optionally substituted alkyl, or silyl; Z 1  and Z 2  are each independently O, S, or optionally substituted alkyl; provided that Q is present at least once in each subunit of formula I.

Metadata:
- Claim Count in Document: 23.0
- Percentile: 96.0
- Lexical Diversity: 1.46341
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['13120389', '14918022', '13575461', '15395221', '12328537']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8191432036084892
- 35 USC 102 Novelty (BERT): 0.6259426464003551
- Combined Prediction Score: 0.7998231478876758
- Mean Citation Score: 502.440568
- Max Citation Score: 653.3163
- Similarity Product: 518.4694551890731

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test